These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 22917556

  • 1. Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5.
    Stiborová M, Poljaková J, Martínková E, Ulrichová J, Simánek V, Dvořák Z, Frei E.
    Toxicology; 2012 Dec 16; 302(2-3):233-41. PubMed ID: 22917556
    [Abstract] [Full Text] [Related]

  • 2. Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases.
    Stiborová M, Indra R, Moserová M, Cerná V, Rupertová M, Martínek V, Eckschlager T, Kizek R, Frei E.
    Chem Res Toxicol; 2012 May 21; 25(5):1075-85. PubMed ID: 22390216
    [Abstract] [Full Text] [Related]

  • 3. Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy.
    Kotrbová V, Mrázová B, Moserová M, Martínek V, Hodek P, Hudeček J, Frei E, Stiborová M.
    Biochem Pharmacol; 2011 Sep 15; 82(6):669-80. PubMed ID: 21683692
    [Abstract] [Full Text] [Related]

  • 4. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.
    Stiborová M, Sejbal J, Borek-Dohalská L, Aimová D, Poljaková J, Forsterová K, Rupertová M, Wiesner J, Hudecek J, Wiessler M, Frei E.
    Cancer Res; 2004 Nov 15; 64(22):8374-80. PubMed ID: 15548707
    [Abstract] [Full Text] [Related]

  • 5. Application of hepatic cytochrome b5/P450 reductase null (HBRN) mice to study the role of cytochrome b5 in the cytochrome P450-mediated bioactivation of the anticancer drug ellipticine.
    Reed L, Indra R, Mrizova I, Moserova M, Schmeiser HH, Wolf CR, Henderson CJ, Stiborova M, Phillips DH, Arlt VM.
    Toxicol Appl Pharmacol; 2019 Mar 01; 366():64-74. PubMed ID: 30685480
    [Abstract] [Full Text] [Related]

  • 6. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
    Stiborová M, Arlt VM, Henderson CJ, Wolf CR, Kotrbová V, Moserová M, Hudecek J, Phillips DH, Frei E.
    Toxicol Appl Pharmacol; 2008 Feb 01; 226(3):318-27. PubMed ID: 17976674
    [Abstract] [Full Text] [Related]

  • 7. The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism.
    Aimová D, Svobodová L, Kotrbová V, Mrázová B, Hodek P, Hudecek J, Václavíková R, Frei E, Stiborová M.
    Drug Metab Dispos; 2007 Oct 01; 35(10):1926-34. PubMed ID: 17656468
    [Abstract] [Full Text] [Related]

  • 8. The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes.
    Stiborová M, Černá V, Moserová M, Mrízová I, Arlt VM, Frei E.
    Int J Mol Sci; 2014 Dec 25; 16(1):284-306. PubMed ID: 25547492
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of human cytochrome P450 3A4 present in liposomal and microsomal nanoparticles in formation of covalent DNA adducts by ellipticine.
    Sulc M, Mrizova I, Cerna T, Frei E, Eckschlager T, Adam V, Kopeckova K, Stiborova M.
    Neuro Endocrinol Lett; 2016 Dec 18; 37(Suppl1):95-102. PubMed ID: 28263536
    [Abstract] [Full Text] [Related]

  • 10. Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes.
    Kotrbová V, Aimová D, Brezinová A, Janouchová K, Poljaková J, Frei E, Stiborová M.
    Neuro Endocrinol Lett; 2006 Dec 18; 27 Suppl 2():18-22. PubMed ID: 17159771
    [Abstract] [Full Text] [Related]

  • 11. Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems.
    Stiborová M, Borek-Dohalská L, Aimová D, Kotrbová V, Kukacková K, Janouchová K, Rupertová M, Ryslavá H, Hudecek J, Frei E.
    Gen Physiol Biophys; 2006 Sep 18; 25(3):245-61. PubMed ID: 17197724
    [Abstract] [Full Text] [Related]

  • 12. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine.
    Stiborová M, Poljaková J, Ryslavá H, Dracínský M, Eckschlager T, Frei E.
    Int J Cancer; 2007 Jan 15; 120(2):243-51. PubMed ID: 17066455
    [Abstract] [Full Text] [Related]

  • 13. Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells.
    Martinkova E, Dontenwill M, Frei E, Stiborova M.
    Neuro Endocrinol Lett; 2009 Jan 15; 30 Suppl 1():60-6. PubMed ID: 20027146
    [Abstract] [Full Text] [Related]

  • 14. Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine.
    Stiborova M, Rupertova M, Schmeiser HH, Frei E.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2006 Jul 15; 150(1):13-23. PubMed ID: 16936898
    [Abstract] [Full Text] [Related]

  • 15. Cytochrome b5 plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine.
    Stiborová M, Indra R, Frei E, Kopečková K, Schmeiser HH, Eckschlager T, Adam V, Heger Z, Arlt VM, Martínek V.
    Monatsh Chem; 2017 Jul 15; 148(11):1983-1991. PubMed ID: 29104319
    [Abstract] [Full Text] [Related]

  • 16. Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.
    Kolarik M, Indra R, Adam V, Heger Z, Kopeckova K, Arlt VM, Stiborova M.
    Neuro Endocrinol Lett; 2019 Feb 15; 39(7):515-524. PubMed ID: 30860683
    [Abstract] [Full Text] [Related]

  • 17. The impact of individual cytochrome P450 enzymes on oxidative metabolism of benzo[a]pyrene in human livers.
    Šulc M, Indra R, Moserová M, Schmeiser HH, Frei E, Arlt VM, Stiborová M.
    Environ Mol Mutagen; 2016 Apr 15; 57(3):229-35. PubMed ID: 26919089
    [Abstract] [Full Text] [Related]

  • 18. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM, Murray M.
    J Pharmacol Exp Ther; 1997 Feb 15; 280(2):966-73. PubMed ID: 9023313
    [Abstract] [Full Text] [Related]

  • 19. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts.
    Stiborová M, Bieler CA, Wiessler M, Frei E.
    Biochem Pharmacol; 2001 Dec 15; 62(12):1675-84. PubMed ID: 11755121
    [Abstract] [Full Text] [Related]

  • 20. Ferrous and ferric state of cytochromes P450 in intact Escherichia coli cells: a possible role of cytochrome P450-flavodoxin interactions.
    Culka M, Milichovsky J, Jerabek P, Stiborova M, Martinek V.
    Neuro Endocrinol Lett; 2015 Dec 15; 36 Suppl 1():29-37. PubMed ID: 26757119
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.